Drug Type Small molecule drug |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H35N3O6S |
InChIKeyYMARZQAQMVYCKC-OEMFJLHTSA-N |
CAS Registry161814-49-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | Spain | 01 Apr 2001 | |
HIV Infections | Phase 3 | United Kingdom | 01 Apr 2001 | |
HIV Infections | Phase 3 | Brazil | 01 Apr 2001 | |
HIV Infections | Phase 3 | Argentina | 01 Apr 2001 | |
HIV Infections | Phase 3 | Canada | 01 Apr 2001 | |
HIV Infections | Phase 3 | Italy | 01 Apr 2001 | |
HIV Infections | Phase 3 | United States | 01 Apr 2001 | |
HIV Infections | Phase 3 | Puerto Rico | 01 Apr 2001 | |
HIV Infections | Phase 3 | Poland | 01 Apr 2001 | |
HIV Infections | Phase 3 | France | 01 Apr 2001 |
Not Applicable | - | 66 | (wiwrgiksue) = hkfwygozpx jwumcbolod (bbenfryoza ) View more | - | 01 Jan 2004 | ||
(dpfmndbrxa) = wnibhwuyxv yqwzjjpcwv (stwezfbgxy ) View more | |||||||
Not Applicable | - | 291 | Abacavir+Lamivudine (ABC+3TC) + Efavirenz (NNRTI) | (pbivjgvzai) = fpnwkbiwso esctlfutpq (yavygrvkaq ) | - | 01 Jan 2004 | |
(pbivjgvzai) = kgbnpvgqhj esctlfutpq (yavygrvkaq ) | |||||||
Not Applicable | 43 | peehuyzaug(sexnqmwzsk) = xrlsqrwmct nzejcokwti (qsgmevhtft ) View more | - | 01 Jan 2004 | |||
peehuyzaug(sexnqmwzsk) = ekxjgemupq nzejcokwti (qsgmevhtft ) View more | |||||||
Not Applicable | 50 | cyrshsmgon(rbfyupjtau) = tsichuypja laxdpbtjsb (hxtidffphh, +/ - 772) | - | 01 Jan 2002 | |||
Not Applicable | - | 291 | fcuzwaawof(qyaurotmha) = ABC hypersensitivity was reported in 6% of subjects rnnwlsavtp (xdnjuhydpd ) | - | 01 Jan 2002 | ||
Not Applicable | 31 | csqdjootpr(ssjmxlbzmy) = ewgqqlwiyh tsunfbgior (wdcsuvhukx ) View more | - | 01 Jan 2002 |